Free Republic

In a Nutshell * An oral compound called TOFA caused significant weight and fat loss in obese mice without reducing food intake or causing muscle loss, setting it apart from current obesity drugs. * TOFA worked by boosting how much energy cells burn, rather than suppressing appetite, and it also improved blood sugar, harmful blood fats, and fatty liver disease. * When combined with semaglutide or tirzepatide, TOFA outperformed either drug alone, and animals maintained their weight loss longer after TOFA treatment ended compared to semaglutide. ============================================================================================== Millions of Americans struggling with obesity have placed their hopes in a new...

Drugs prescribed for diabetes and chronic obesity such as Ozempic are increasingly sought after for quick, cosmetic weight loss, a life choice pharmacists warn can lead to serious health risks. “We have seen thin people try to come in and get it,” Dr. Carrie Leske, a licensed pharmacist in Minnesota, recently told Just the News. “As pharmacists we are supposed to use our judgment and, if need be, call the physician and try to understand what's going on, because it's supposed to only be used for obese people.” Such prescription medications, known under such popular brand names as Ozempic and...

Key Points Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing for approval of the weekly injection, called retatrutide, which works differently from existing injections and pills. The highest dose of retatrutide helped patients lose 28.3% of their weight — or 70.3 pounds — on average over 80 weeks. ==================================================================== VIDEO AT LINK........ Eli Lilly on Thursday said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring...

A major new study reveals that combining the weight-loss drug tirzepatide with menopause hormone therapy leads to significantly greater fat loss in postmenopausal women. Women using both therapies saw an average weight loss of 17%—compared to just 14% with tirzepatide alone—and were more than twice as likely to lose 20% or more of their body weight. Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Postmenopausal Women Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone, according to a study being...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, according to featured clinical research. In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and HFpEF. HFpEF occurs when the heart muscle cannot enlarge sufficiently to accommodate the blood it receives, causing pressure in the heart to become elevated. Chronic kidney disease occurs when the kidneys do not filter waste from the blood as they should, leading to a buildup of toxins. Tirzepatide...

Novel drug treatment developed for diabetes shows promising results of enhanced sleep and overall health for patients diagnosed with obesity and living with obstructive sleep apnea ================================================================== Researchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study demonstrating the potential of tirzepatide, known to manage type 2 diabetes, as the first effective drug therapy for obstructive sleep apnea (OSA), a sleep-related disorder characterized by repeated episodes of irregular breathing due to complete or partial blockage of the upper airway. The results, published in the June 21, 2024 online edition of New...

Americans may love to eat junk, but we’re nearly as passionate about doing penance, with more than half of us scarfing down dietary supplements on a regular basis. From herbal remedies to energy boosters, vitamins and weight-loss pills, supplements form a massive global industry — one that’s expected to reach $200 billion in value by 2025, according to the AMA Journal of Ethics. Trouble is, it’s a largely “Wild West” scene — and that’s by design, believe it or not. The Dietary Supplement Health and Education Act of 1994 limits the ability of the Food and Drug Administration to regulate...

An experimental drug being clinically investigated for its effects on body weight in obese and overweight people has delivered record-breaking weight loss for participants in the trial – on par with surgical options, the company behind the drug suggests. Tirzepatide, developed by American pharmaceutical company Eli Lilly and Company (Lilly), is a once-weekly injection that promotes weight loss by mimicking the effects of natural hormones called incretins. These hormones lower blood sugar after we eat, in addition to regulating metabolic processes related to digestion. In the case of tirzepatide, which is not yet available on the market pending further clinical...